



OFFICE of the DEPUTY PRIME MINISTER
MINISTRY for HEALTH
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

DH CIRCULAR No. 69/2020
DH 903/2020

2nd October 2020

Attention All: Consultants
Medical Officers
Pharmacists
Pharmacy Technicians
Nurses

Re: Umeclidinium 55 micrograms/dose dry powder inhaler

It is being brought to your attention that umeclidinium 55micrograms/dose dry powder inhaler is now available on the Government Formulary List (GFL).

Umeclidinium is a long-acting muscarinic receptor antagonist (LAMA) and can be prescribed by Consultant Respiratory Physicians as per protocol 111 (Annex 1).

For your attention please.

Dr Denis Vella Baldacchino
Chief Medical Officer

Long-Acting Muscarinic Receptor Antagonist

Prescriber criteria: Consultant Respiratory Physician

Out-patient and In-patient use:

1. Chronic Obstructive Pulmonary Disease

Reserved for:

- Mild/moderate COPD in patients not controlled on short-acting beta₂ agonists
- Severe COPD as add-on therapy in patients who are not controlled with monotherapy.

Duration of Approval:

Up to 3 years or as directed by consultant